Emcure Pharma (NSE:EMCURE, BOM:544210) and Novo Nordisk India have partnered to introduce Poviztra, a 2.4 mg semaglutide injection, in India, according to an Indian bourse filing on Monday.

Under the agreement, Emcure will exclusively distribute and market the product across pharmacies and regions beyond Novo Nordisk's existing network, the filing said.

Poviztra is a secondary brand of Wegovy, which was introduced in India in June. It is prescribed alongside a calorie-controlled diet and increased physical activity to support long-term weight management and help lower the risk of major cardiovascular events in people who are overweight or obese.

The collaboration aims to expand access to safe and effective weight management therapies for a broader patient base across India, the companies said in the joint statement.